Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revestive all-case post-marketing surveillance in short bowel syndrome
jRCT2031210284Completed
- Sponsor
- Takeda
- Start
- Sep 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of teduglutide in short bowel syndrome (SBS), sponsored by Takeda. Primary endpoints: Number of participants with adverse events and Number of participants with serious adverse events. Started Sep 2021; status: completed.
02
Drugs
teduglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on jRCT2031210284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210284.